BidaskClub Upgrades Vericel (VCEL) to “Buy”

Vericel (NASDAQ:VCEL) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday.

Several other equities research analysts have also recently commented on VCEL. BTIG Research boosted their target price on Vericel from $17.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, November 6th. Needham & Company LLC boosted their target price on Vericel to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 6th. Finally, Oppenheimer started coverage on Vericel in a report on Tuesday, January 29th. They issued an “outperform” rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Vericel currently has a consensus rating of “Buy” and a consensus price target of $17.98.

Shares of NASDAQ:VCEL opened at $18.71 on Wednesday. Vericel has a 12 month low of $7.90 and a 12 month high of $21.00. The company has a market cap of $848.30 million, a P/E ratio of -37.42 and a beta of 2.92. The company has a current ratio of 7.96, a quick ratio of 7.71 and a debt-to-equity ratio of 0.14.

Vericel (NASDAQ:VCEL) last announced its earnings results on Tuesday, February 26th. The biotechnology company reported $0.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.07. Vericel had a negative return on equity of 17.39% and a negative net margin of 15.80%. The firm had revenue of $31.34 million for the quarter, compared to analysts’ expectations of $28.69 million. During the same quarter in the previous year, the company earned $0.01 earnings per share. The firm’s quarterly revenue was up 34.2% compared to the same quarter last year. As a group, analysts anticipate that Vericel will post -0.23 earnings per share for the current fiscal year.

In other Vericel news, CFO Gerard J. Michel sold 10,000 shares of the company’s stock in a transaction on Monday, February 11th. The stock was sold at an average price of $17.09, for a total value of $170,900.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Gerard J. Michel sold 15,625 shares of the company’s stock in a transaction on Monday, December 10th. The shares were sold at an average price of $16.81, for a total value of $262,656.25. Following the completion of the transaction, the chief financial officer now directly owns 160,960 shares in the company, valued at approximately $2,705,737.60. The disclosure for this sale can be found here. Insiders sold 65,336 shares of company stock worth $1,112,761 in the last ninety days. 4.70% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in Vericel by 3.5% during the 4th quarter. BlackRock Inc. now owns 2,966,530 shares of the biotechnology company’s stock valued at $51,618,000 after purchasing an additional 100,687 shares during the period. Vanguard Group Inc raised its stake in Vericel by 18.2% during the 3rd quarter. Vanguard Group Inc now owns 2,363,346 shares of the biotechnology company’s stock valued at $33,441,000 after purchasing an additional 363,705 shares during the period. Vanguard Group Inc. raised its stake in Vericel by 18.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,363,346 shares of the biotechnology company’s stock valued at $33,441,000 after purchasing an additional 363,705 shares during the period. RTW Investments LP raised its stake in Vericel by 3.2% during the 4th quarter. RTW Investments LP now owns 2,289,134 shares of the biotechnology company’s stock valued at $39,831,000 after purchasing an additional 71,218 shares during the period. Finally, Northern Trust Corp raised its stake in Vericel by 1.5% during the 4th quarter. Northern Trust Corp now owns 550,249 shares of the biotechnology company’s stock valued at $9,575,000 after purchasing an additional 8,260 shares during the period. 76.74% of the stock is currently owned by institutional investors.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Read More: How is inflation measured?

Analyst Recommendations for Vericel (NASDAQ:VCEL)



Leave a Reply